Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + pazopanib
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Tislelizumab + pazopanib is a combination therapy being investigated for the treatment of advanced renal cell carcinoma. Tislelizumab is a humanized IgG4 monoclonal antibody designed to bind to the programmed cell death protein 1 (PD-1) receptor, thereby blocking its interaction with PD-L1 and PD-L2 and restoring the anti-tumor activity of T cells. Pazopanib is an orally active, multi-targeted tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-alpha and -beta), and the stem cell factor receptor (c-Kit). By combining these two agents, the therapy aims to achieve a synergistic effect by simultaneously inhibiting tumor angiogenesis and enhancing the immune system's ability to recognize and destroy cancer cells. This specific combination is being evaluated in clinical trials sponsored by institutions such as The First Affiliated Hospital of Xinjiang Medical University.
- Other names
- Baizean + Votrient
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR3 (Fibroblast growth factor receptor 3)FLT3 (Fms related receptor tyrosine kinase 3)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)UGT1A1 (UDP-glucuronosyltransferase 1A1)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on tislelizumab + pazopanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + pazopanib.